BioSpace News Archive

Lipocine Inc. announces positive topline results from its Open Label Extension study, OLE. LPCN 1144 comprises an orally delivered prodrug of testosterone.

On World Fibromyalgia Awareness Day ( May 12 ), the French startup Remedee Labs is announcing that the FDA has granted Breakthrough Device Designation to its endorphin stimulator for fibromyalgia patients.

Wysa, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its AI-based digital mental health conversational agent for patients 18 years and older with a diagnosis of chronic musculoskeletal pain (defined as pain lasting longer than three months) and depression and anxiety.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it is resuming share repurchases with excess free cash flow in accordance with the company’s disciplined approach to capital allocation.

Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir ® Digihaler ® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting.

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Aptevo Therapeutics Inc. today reported financial results and business highlights for the quarter ended March 31, 2022.

Rockwell Medical, Inc. (Nasdaq: RMTI), today announced that it provided the U.S. Food and Drug Administration (FDA) with the supplemental data, requested by the agency in December 2021, for the Company’s pending Investigational New Drug (IND) application in support of a proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC).

Equillium, Inc. announced that the European Hematology Association has published an abstract highlighting the Phase 3 EQUATOR study in first-line acute graft-versus-host disease.

Alto Neuroscience today announced that founder and chief executive officer, Amit Etkin, M.D., Ph.D., has been appointed to serve as a member of the National Institute on Drug Abuse’s (NIDA) National Advisory Council on Drug Abuse (NACDA).